Validating fatty acid binding protein 3 as a diagnostic and prognostic biomarker for peripheral arterial disease: a three-year prospective follow-up study
Abdelrahman Zamzam(St. Michael's Hospital), Mohammad Qadura(University of Toronto), Rawand Abdin(McMaster University), Muzammil H. Syed(St. Michael's Hospital), John W. Eikelboom(Population Health Research Institute), Ori D. Rotstein(St. Michael's Hospital), David J. Klein(St. Michael's Hospital), Krishna K. Singh(Western University)
Cited by 17
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
|New England Journal of Medicine|2017|2.4k
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
|New England Journal of Medicine|2013|1.5k